Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Levi & Korsinsky Announces an Investigation on Behalf of Agenus Inc. (AGEN) Shareholders Who May Have Been Affected by Fraud
05:15pm, Friday, 19'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal
AGEN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Agenus Inc.
05:00pm, Friday, 19'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal
Shareholder Rights Advocates at Levi & Korsinsky Investigate Agenus Inc. (AGEN) Regarding Possible Securities Fraud Violations
05:00pm, Friday, 19'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal
Investors Of Agenus Inc Have The Chance To Participate In The Securities Fraud Probe By The Schall Law Firm
05:00pm, Friday, 19'th Jul 2024
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Age
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
01:00pm, Friday, 19'th Jul 2024
Thursday, Agenus Inc. AGEN announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for adult patients with
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
11:41am, Friday, 19'th Jul 2024
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inves
Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "Herpes Simplex Virus Infections - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Her
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agenus Inc. - AGEN
08:50pm, Thursday, 18'th Jul 2024
NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN). Such investors are advised to contact
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Inves
Why Is Agenus (AGEN) Stock Down 55% Today?
10:42am, Thursday, 18'th Jul 2024
Agenus (NASDAQ: AGEN ) stock is falling hard on Thursday after the clinical-stage biotechnology company provided results from a Phase 2 clinical trial of botensilimab and balstilimab as a colorectal
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-s
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
07:00am, Monday, 17'th Jun 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr.
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immunotherapy combination for treating micro
Agenus Announces Virtual Annual Shareholders Meeting
07:30am, Tuesday, 04'th Jun 2024
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annua
